BACKGROUND: Opioids are known to induce delirium, but few studies have closely investigated differences in incidence of delirium among different opioids. OBJECTIVES: To determine whether there is a clinically significant difference in the incidence of delirium between oral opioids in previously opioid-naive patients. METHODS: Subjects were 259 opioid-naive in-patients with cancer who were started on morphine sulfate, oxycodone hydrochloride, or tapentadol hydrochloride extended-release tablets at our hospital between August 1, 2014, and September 30, 2018. The incidence of delirium during the first week of treatment was compared between the drugs. RESULTS: The incidence of delirium was 4.8% (n = 83) for morphine sulfate, 6.9% (n = 131) for oxycodone hydrochloride, and 6.7% (n = 45) for tapentadol hydrochloride. The incidence did not significantly differ between oxycodone hydrochloride (OR = .69, 95% CI = .20-2.30, P [Fisher's exact test] = .77) or tapentadol hydrochloride (OR = .71, 95% CI = .15-3.32, P [Fisher's exact test] = .70) and morphine sulfate (reference group). Moreover, the incidence did not significantly differ between tapentadol hydrochloride (OR = 1.03, 95% CI = .27-3.00, P [Fisher's exact test] = 1.00) and oxycodone hydrochloride (reference group). CONCLUSION: The incidence of delirium in previously opioid-naive patients did not differ significantly among morphine sulfate, oxycodone hydrochloride, and tapentadol hydrochloride extended-release tablets, suggesting similar risk of delirium in opioid-naive patients among these oral opioids.
BACKGROUND: Opioids are known to induce delirium, but few studies have closely investigated differences in incidence of delirium among different opioids. OBJECTIVES: To determine whether there is a clinically significant difference in the incidence of delirium between oral opioids in previously opioid-naive patients. METHODS: Subjects were 259 opioid-naive in-patients with cancer who were started on morphine sulfate, oxycodone hydrochloride, or tapentadol hydrochloride extended-release tablets at our hospital between August 1, 2014, and September 30, 2018. The incidence of delirium during the first week of treatment was compared between the drugs. RESULTS: The incidence of delirium was 4.8% (n = 83) for morphine sulfate, 6.9% (n = 131) for oxycodone hydrochloride, and 6.7% (n = 45) for tapentadol hydrochloride. The incidence did not significantly differ between oxycodone hydrochloride (OR = .69, 95% CI = .20-2.30, P [Fisher's exact test] = .77) or tapentadol hydrochloride (OR = .71, 95% CI = .15-3.32, P [Fisher's exact test] = .70) and morphine sulfate (reference group). Moreover, the incidence did not significantly differ between tapentadol hydrochloride (OR = 1.03, 95% CI = .27-3.00, P [Fisher's exact test] = 1.00) and oxycodone hydrochloride (reference group). CONCLUSION: The incidence of delirium in previously opioid-naive patients did not differ significantly among morphine sulfate, oxycodone hydrochloride, and tapentadol hydrochloride extended-release tablets, suggesting similar risk of delirium in opioid-naive patients among these oral opioids.
Authors: Wolfgang Schröder; Jean De Vry; Thomas M Tzschentke; Ulrich Jahnel; Thomas Christoph Journal: Eur J Pain Date: 2010-06-11 Impact factor: 3.931
Authors: S M Weinstein; L Poultsides; L R Baaklini; E E Mörwald; C Cozowicz; J N Saleh; M B Arrington; J Poeran; N Zubizarreta; S G Memtsoudis Journal: Br J Anaesth Date: 2018-03-09 Impact factor: 9.166
Authors: Robert A Swarm; Judith A Paice; Doralina L Anghelescu; Madhuri Are; Justine Yang Bruce; Sorin Buga; Marcin Chwistek; Charles Cleeland; David Craig; Ellin Gafford; Heather Greenlee; Eric Hansen; Arif H Kamal; Mihir M Kamdar; Susan LeGrand; Sean Mackey; M Rachel McDowell; Natalie Moryl; Lisle M Nabell; Suzanne Nesbit; Nina O'Connor; Michael W Rabow; Elizabeth Rickerson; Rebecca Shatsky; Jill Sindt; Susan G Urba; Jeanie M Youngwerth; Lydia J Hammond; Lisa A Gurski Journal: J Natl Compr Canc Netw Date: 2019-08-01 Impact factor: 11.908
Authors: Jo Ellen Wilson; Matthew F Mart; Colm Cunningham; Yahya Shehabi; Timothy D Girard; Alasdair M J MacLullich; Arjen J C Slooter; E Wesley Ely Journal: Nat Rev Dis Primers Date: 2020-11-12 Impact factor: 65.038
Authors: G W Hanks; F Conno; N Cherny; M Hanna; E Kalso; H J McQuay; S Mercadante; J Meynadier; P Poulain; C Ripamonti; L Radbruch; J R Casas; J Sawe; R G Twycross; V Ventafridda Journal: Br J Cancer Date: 2001-03-02 Impact factor: 7.640
Authors: Lieke M Swart; Vera van der Zanden; Petra E Spies; Sophia E de Rooij; Barbara C van Munster Journal: Drugs Aging Date: 2017-06 Impact factor: 3.923